Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program
The Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program at Children's Hospital of Philadelphia (CHOP) is the premier national and international center for the therapeutic development and advanced clinical care of inherited bleeding disorders. This program combines our established clinical expertise in hemophilia gene therapy and management of bleeding disorders with our research strengths. Our goal is to develop new therapies for bleeding disorders and to safely and efficiently integrate novel therapies into care for patients. We offer:
- State-of-the-art clinical care and a gene therapy program for adolescents and young adults with hemophilia
- Consultation for novel therapies for hemostatic disorders
- Identification and management of unclassified bleeding disorders
The NoT Bleeding Program is co-led by a team of world-class experts who together have more than two decades of clinical experience in gene therapy for hemophilia and in innovating care for patients with bleeding disorders.